Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Malay Mail on MSN1d
How are bias, religious background and prejudice affecting HIV harm reduction in Malaysia? Doctors relate their experienceSeveral urged for increased education and awareness among healthcare providers to reduce stigma when treating HIV patients in ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
"Madagascar’s HIV epidemic is being fueled by gaps in prevention and glaring inequalities, which urgently need to be ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback